Children of Six to 11 Years will Now Benefit from Xolair Injections
As per recent reports, children of ages between six and 11 will now be given Xolair injections for the first time. The move is considered for helping the children with severe asthma.
The drug received approval from the National Institute for Health and Care Excellence (NICE) in 2007. Since then, the drug has been used to treat the condition in about 2,000 severely ill patients. However, in November, NICE said that Xolair was not much affordable and effective than it was previously thought.
Therefore, the agency made an announcement under which it said the drug should not be given to the new patients. The proposal was criticized by the patients and doctors. A charity named Asthma UK claimed the drug has proved life saving in many cases.
But according to reports, NICE has yesterday taken U-turn on its decision. For the first time ever, the drug has been made available for the children of ages between six and 11. The drug is already available to children and adults in Scotland.
"While it's not suitable for everyone, people with severe allergic asthma who benefit from taking Xolair can see a massive improvement in their quality of life", said Dr. Samantha Walker, of Asthma UK.
New Zealand News
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- CATL and LG Energy account for nearly 54% of global xEV battery market: SNE Research
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids
- Italy’s ASPI announces plans to install cross-country ultra-fast EV charging network
- EV ownership costs significantly lower than conventional models: French Study